Effects of Ketamine and Risperidone on Cognition
NCT01140620 · Schiz_2 · University of Manchester
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Biconditional learning task
Measured over 6 months
Eye movement task
Measured over 6 months
Salience Attribution task
Measured over 6 months
Signal detection task
Measured over 6 months
N-Back
Measured over 6 months
Spatial working memory
Measured over 6 months
Verbal Fluency
Measured over 6 months
Event-related potentials (Manchester EEG pilot study only)
Measured over 6 months
Questionnaires and assessment scale scores
Measured over 6 months
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
3 study sites
| Facility | City | Region | Country |
|---|---|---|---|
| Institute of Psychiatry, King's College London | London | Greater London | United Kingdom |
| University of Manchester (Dept of Neuropyschiatry) | Manchester | Manchester | United Kingdom |
| School of Psychology, University of Cardiff | Cardiff | — | United Kingdom |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT01140620 on ClinicalTrials.gov →
Last updated in the registry 2016-11-09. Registry records change; this page reflects the data build of 2026-08-25.
Related
Where this trial sits
Substance
Indication